Research programme: antitussives - UCBAlternative Names: Antitussives research programme - UCB; CP1
Latest Information Update: 26 May 2005
At a glance
- Originator UCB
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cough
Most Recent Events
- 26 May 2005 Discontinued - Preclinical for Cough (Inhalation)
- 05 Nov 2002 Preclinical trials in Cough (Inhalation)
- 05 Nov 2002 UCB has acquired Cardiome Pharma's preclinical anti-tussive programme